Sangivamycin
Sangivamycin is a natural product originally isolated from "Streptomyces rimosus", which is a nucleoside analogue. It acts as an inhibitor of protein kinase C. It has antibiotic, antiviral and anti-cancer properties and has been investigated for various medical applications, though never approved for clinical use itself. However, a number of related derivatives continue to be researched.

Oyagen, a biotechnology company, has been developing sangivamycin or OYA1, which showed effecacy against Ebola infections, as a broad spectrum antiviral for COVID-19. Tonix Pharmaceuticals licensed OYA1 from Oyagen in April 2021 to develop it for the treatment of COVID-19 and it is now called TNX-3500. 
Q901227
natural product
Concept
Q7623395
Streptomyces rimosus
Concept
Q2689559
nucleoside analogue
Concept
Q420877
protein kinase C
Concept
Q12187
antibiotic
Concept
Q846227
antiviral
Concept
Q39052499
Tonix Pharmaceuticals
ORG
Q27158840
Sangivamycin
MISC
2021-04-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
April 2021
DATE
+1^^http://www.w3.org/2001/XMLSchema#decimal
1
NUMBER
-19^^http://www.w3.org/2001/XMLSchema#decimal
-19
NUMBER
+1^^http://www.w3.org/2001/XMLSchema#decimal
1
NUMBER
-19^^http://www.w3.org/2001/XMLSchema#decimal
-19
NUMBER
-3500^^http://www.w3.org/2001/XMLSchema#decimal
-3500
NUMBER
subject has role